BridgeBio have substantially improved the progress of the new therapy for cardiac amyloidosis, leveraging the investigational drug. Initial clinical information reveals potential outcomes for patients affected by this debilitating disease. The effort represents researchers’ commitment to treating critical healthcare demands in a heart space. Att